Communiqués Exagen Inc.

Actions

XGN

US30068X1037

Temps Différé Nasdaq Autres places de cotation 17:05:47 17/07/2024			Varia. 5j.	Varia. 1 janv.
2,02 ^USD	-6,48 %		+8,60 %	+1,51 %

14/05	EXAGEN INC. : Cantor Fitzgerald reste à l'achat	ZM
13/05	Exagen Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year	13/05	GL
Exagen Announces Campaign for Lupus Awareness Month	06/05	GL
Exagen to Announce First Quarter 2024 Results on May 13, 2024	30/04	GL
Exagen to Announce First Quarter 2024 Results on May 13, 2024	30/04	AQ
Exagen Inc. Announces Changes to the Board of Directors	29/04	AQ
Exagen Inc. Announces Changes to the Board of Directors	26/04	GL
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results	18/03	GL
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results	18/03	AQ
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum	08/03	GL
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum	08/03	AQ
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024	07/03	GL
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference	30/01	GL
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance	07/01	AQ
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance	07/01	GL
Exagen Inc. Reports Strong Third Quarter 2023 Results	13/11	GL
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers	09/11	GL
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum	02/11	GL
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum	02/11	AQ
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023	30/10/23	GL
Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting	28/09/23	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Exagen Inc.

Actions

XGN

US30068X1037

Communiqués

Filtres